AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32241789
Drug: True acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True acupuncture treatment
Trial: 32049937
Drug: Weekly teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly teriparatide (WT) from 1 week to 6 months postoperatively
Trial: 35465375
Drug: Standard ward
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ward pre-operative preparation procedures
Trial: 33055078
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg intravenous, two infusions 4 weeks apart)
Trial: 32602828
Drug: Transarterial radioembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial radioembolization (TARE) with a tumor radiation-absorbed dose greater than or equal to 100 Gy (n = 67)
Trial: 32602828
Drug: Transarterial radioembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial radioembolization (TARE) with tumor radiation-absorbed dose greater than or equal to 100 Gy and optimal agreement
Trial: 34157632
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) 1500 mg
Trial: 33864548
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) (n=33)
Trial: 32915043
Drug: hypCPT (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypCPT (cognitive processing therapy + hypnosis)
Trial: 32915043
Drug: ssmCPT (sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ssmCPT (sleep and psychiatric symptom monitoring plus cognitive processing therapy)
Trial: 32432718
Drug: Polymer-free, biolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer-free, biolimus A9-eluting drug-coated stent with 1-month dual antiplatelet therapy
Trial: 34489860
Drug: Metformin only
RxNorm normalized name: Metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin only (Control)
Trial: 35121639
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg
Trial: 34984839
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI, 80 U)
Trial: 32979620
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) prior to TBLB
Trial: 33073298
Drug: Adipose tissue
RxNorm normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue stem cell-derived exosomes gel
Trial: 34550563
Drug: Dexmedetomidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2 µg kg-1 h-1)
Trial: 34550563
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.5 ml kg-1 h-1)
Trial: 33176942
Drug: JUUL System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL System (JS) in four flavors (Virginia Tobacco, Mango, Mint, Creme, [5.0 % nicotine; 59 mg/mL])
Trial: 38695479
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + chemotherapy
Trial: 36410666
Drug: Daily TPTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TPTD (20 μg daily)
Trial: 36410666
Drug: Cyclic TPTD
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic TPTD (20 μg daily for 3 months followed by 3 months off)
Trial: 36432461
Drug: Daily walnut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily walnut consumption
Trial: 32533012
Drug: GG genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GG genotype at rs4680 G > A
Trial: 32533012
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype at rs4633
Trial: 36362620
Drug: Intensified clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified clinical pharmacological/pharmaceutical care program
Trial: 33087145
Drug: Re-esterified DHA
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-esterified DHA (975 mg for 30 days)
Trial: 38050037
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg once a week
Trial: 33596968
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided ESP block with 40 ml 0.25% levo-bupivacaine (20 ml each side) post induction of general anaesthesia and before surgical incision.
Trial: 33596968
Drug: Standardised analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised analgesic protocol (same for both groups).
Trial: 35271495
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (ascorbic acid) administered three times a week for three months
Trial: 35340961
Drug: 0.5% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isobaric levobupivacaine with 75‐mg magnesium sulfate
Trial: 35340961
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine with 75‐mg magnesium sulfate
Trial: 32951292
Drug: Gracilaria algae
RxNorm normalized name: GRACILARIA GRACILIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gracilaria algae cream 3%
Trial: 32951292
Drug: Clobetasol cream
RxNorm normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol cream 0.05%
Trial: 35706490
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenous ferric carboxymaltose (iron)
Trial: 33961310
Drug: Domagrozumab 5
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 5 mg/kg every 4 weeks
Trial: 33961310
Drug: Domagrozumab 20
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 20 mg/kg every 4 weeks
Trial: 33961310
Drug: Domagrozumab 40
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 40 mg/kg every 4 weeks
Trial: 35759733
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) 135 mg/m2 once every 28 days for 12 cycles
Trial: 35759733
Drug: Paclitaxel poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel poliglumex (PP) 135 mg/m2 once every 28 days for 12 cycles
Trial: 34530679
Drug: Wait-list condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list condition with treatment advice (WL/TA)
Trial: 32049627
Drug: Phosphate content
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate content in medications prescribed to HD patients
Trial: 32049627
Drug: Monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of medications containing phosphate
Trial: 34969033
Drug: Treat-and-extend (T&E)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treat-and-extend (T&E) regimen with intravitreal ranibizumab 0.5 mg
Trial: 34969033
Drug: Once-monthly to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly to treat-and-extend (OM-T&E) regimen with intravitreal ranibizumab 0.5 mg
Trial: 34969033
Drug: Once-monthly to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly to treat-and-extend (OM-T&E) regimen
Trial: 36190330
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SAp and SAm
Trial: 32965037
Drug: High-dose melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melatonin (4 mg for <40 kg; 8 mg for ≥40 kg)
Trial: 32965037
Drug: Low-dose melatonin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose melatonin (1 mg for <40 kg; 2 mg for ≥40 kg)
Trial: 32965037
Drug: High-dose melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melatonin
Trial: 32965037
Drug: Low-dose melatonin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose melatonin
Trial: 39222391
Drug: Oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation
Trial: 34836393
Drug: 52 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 mL/day of EVOO (n = 50)
Trial: 34836393
Drug: DieTBra +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DieTBra + 52 mL/day of EVOO (n = 50)
Trial: 34822251
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic (group A)
Trial: 34822251
Drug: No anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anaesthetic gel (group B)
Trial: 33080415
Drug: Norepinephrine 4
RxNorm normalized name: norepinephrine 4 MG per 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 4 μg/min
Trial: 35281034
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (15 µg daily for 12 weeks)
Trial: 35281034
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 (15 µg daily for 12 weeks)
Trial: 35281034
Drug: Placebo (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (not specified dosage or duration)
Trial: 33290248
Drug: Routine diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine diabetes care after discontinuation of rosiglitazone
Trial: 32631074
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (simulated microcurrent electrical nerve stimulation) 5 days/week
Trial: 32660521
Drug: Medium-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-volume preparation
Trial: 34779576
Drug: Upadacitinib (UPA)
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib (UPA) 15 mg
Trial: 33472997
Drug: Closed-loop target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop target controlled infusion (CLTCI) of propofol
Trial: 33472997
Drug: Open-loop target
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop target controlled infusion (OLTCI) of propofol
Trial: 33628012
Drug: Bilayer tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilayer tablet of gemigliptin/rosuvastatin 50/20 mg
Trial: 33628012
Drug: Monolayer tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monolayer tablet of gemigliptin/rosuvastatin 50/20 mg
Trial: 33577389
Drug: Over-minus therapy
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-minus therapy
Trial: 33577389
Drug: Over-minus therapy
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-minus therapy with inward decentration of spectacle glasses
Trial: 34444341
Drug: Physical literacy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical literacy-based intervention once weekly for 14 weeks
Trial: 33503173
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine tablets combined with celecoxib
Trial: 33503173
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine tablets alone (Control)
Trial: 32100681
Drug: Nutrition intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition intervention including lipid‐based nutrient supplements
Trial: 33777422
Drug: Personalised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised physical activity consultations, pedometers, monthly messages via web-based application
Trial: 34563169
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg daily, orally)
Trial: 33374947
Drug: 3 mg/kg/bm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/bm of caffeine (3COF)
Trial: 33374947
Drug: 6 mg/kg/bm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg/bm of caffeine (6COF)
Trial: 38077080
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (eTAU)
Trial: 33895220
Drug: Optimal PEEP
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal PEEP (8.8 ± 2.4 cmH2O) with decremental titration after ARM
Trial: 33601948
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) with 120 ml ropivacaine 0.2% plus epinephrine 0.5 µ/ml
Trial: 33383447
Drug: SSS07 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSS07 (5, 15, 30, 50, 75, and 100 mg)
Trial: 33383447
Drug: SSS07 (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSS07 (lower doses)
Trial: 33383447
Drug: SSS07 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSS07 (100 mg)
Trial: 34049916
Drug: Daily Mile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Mile schools (intervention group)
Trial: 34049916
Drug: Non-Daily Mile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Daily Mile schools (control group)
Trial: 32068436
Drug: NN‐Asp (originator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN‐Asp (originator insulin aspart)
Trial: 35778368
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (LiSWT)
Trial: 35665521
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg t.i.d.
Trial: 32061505
Drug: Empiric broad-spectrum
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric broad-spectrum antibiotic therapy
Trial: 32061505
Drug: Initial oral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial oral or parenteral therapy
Trial: 32061505
Drug: Shorter courses
RxNorm normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter courses of therapy
Trial: 32061505
Drug: Antibiotic time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic time out protocol
Trial: 34986194
Drug: Dietary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intervention of minimal and unprocessed foods for three to six months, including five times per week green vegetables, three times per week beef, daily 200-300 mL whole cow's milk (3.4% fat), and whole dairy butter (80% fat) on each slice of bread.
Trial: 33323442
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (3 g/day of n-3 polyunsaturated fatty acids)
Trial: 34560806
Drug: Reduced-dose alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose alteplase regimen
Trial: 34560806
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin anticoagulation
Trial: 33538113
Drug: Tanezumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 2.5 mg subcutaneously every 8 weeks
Trial: 33538113
Drug: Tanezumab 5
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 5 mg subcutaneously every 8 weeks
Trial: 33538113
Drug: NSAIDs (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (oral naproxen, celecoxib, or diclofenac twice daily)
Trial: 33993064
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (TTh) for 2 years
Trial: 32844712
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during the first year, followed by Testosterone therapy (TTh) during the second year
Trial: 35418412
Drug: Test-and-treat plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test-and-treat plus L. reuteri
Trial: 35418412
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus L. reuteri
Trial: 33554885
Drug: Low power
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low power laser therapy (LPLT) for 15 sessions
Trial: 34542830
Drug: Galcanezumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab (120 mg/month with 240 mg loading dose)
Trial: 34542830
Drug: Galcanezumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab (120 mg/month)
Trial: 33109271
Drug: Group Post‐Admission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Post‐Admission Cognitive Therapy for Suicidality (GPACTS)
Trial: 38176391
Drug: Individual Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Supportive Therapy (IST)
Trial: 32348539
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection every 4 weeks (2q4)
Trial: 32348539
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection every 8 weeks (2q8)
Trial: 36047018
Drug: Limited protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited protocol (LP) - limited-frequency ultrasound monitoring (only at end of treatment)
Trial: 35046508
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo (n=54)
Trial: 35046508
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ketamine (0.2 mg/kg; n=53)
Trial: 35046508
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose ketamine (0.5 mg/kg; n=51)
Trial: 33909353
Drug: Acupuncture as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture as adjunctive therapy
Trial: 34655432
Drug: Cetagliptin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetagliptin 400 mg
Trial: 34655432
Drug: Cetagliptin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetagliptin (various doses 12.5-400 mg)
Trial: 35579606
Drug: Moderate walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate walking exercise (150 minutes weekly, 3 times a week for 12 weeks)
Trial: 35579606
Drug: Vigorous walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigorous walking exercise (75 minutes weekly, 3 times a week for 12 weeks)
Trial: 36129240
Drug: TAT patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAT patch
Trial: 34447995
Drug: Early rhythm
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rhythm control therapy in asymptomatic patients (395/801)
Trial: 34447995
Drug: Early rhythm
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rhythm control therapy in symptomatic patients
Trial: 34215703
Drug: belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10 mg/kg every 28 days for ?7 years
Trial: 35304924
Drug: adamgammadex 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adamgammadex 2 mg.kg-1
Trial: 35304924
Drug: adamgammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adamgammadex 4 mg.kg-1
Trial: 35304924
Drug: adamgammadex 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adamgammadex 6 mg.kg-1
Trial: 35304924
Drug: adamgammadex 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adamgammadex 8 mg.kg-1
Trial: 33359562
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (NDT group)
Trial: 35134489
Drug: Henna mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henna mouthwash (2% aqueous extract, prescribed twice daily)